Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Swelling of eyelid, Vision blurred
Clinical narrative: This case was initially received via an unknown source (no reference has been entered for a health authority or license partner) on 19-Feb-2021. The most recent information was received on 29-Jun-2021 and was forwarded to Moderna on 29-Jun-2021. This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (headache/intense localized headache), ERYTHEMA (scalp redness/redness), HERPES ZOSTER (Shingles), BLOOD PRESSURE INCREASED (elevated blood pressure) and RASH (rash breakout on forhead and eyelide (unable to open)) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042120A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.  The patient's past medical history included Osteoporosis (no medical history) on 11-Jul-2014 and Cholesterol since 02-Jan-2014. Concomitant products included VITAMIN B COMPLEX from 20-Jun-2011 to an unknown date for Vitamin B complex deficiency NOS, ALENDRONATE SODIUM from 11-Jul-2014 to an unknown date, ATORVASTATIN from 18-Dec-2019 to an unknown date, CALCIUM, MAGNESIUM, ZINC (CALCIUM MAGNESIUM ZINC [CALCIUM;MAGNESIUM;ZINC]) from 20-Jun-2011 to an unknown date and VITAMIN B NOS from 20-Jun-2011 to an unknown date for an unknown indication. On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 2 dosage form. On 14-Feb-2021, the patient experienced HERPES ZOSTER (Shingles), RASH (rash breakout on forhead and eyelide (unable to open)), SWELLING OF EYELID (unable to opne eye due to swollan watery eyelid) and VISION BLURRED (vision was densly blurry). On 04-Mar-2021, the patient experienced PHOTOPHOBIA (light senstivity/tearing frequently) and LACRIMATION INCREASED (light senstivity/tearing frequently). On an unknown date, the patient experienced HEADACHE (headache/intense localiged headache), ERYTHEMA (scalp redness/redness), BLOOD PRESSURE INCREASED (elevated blood pressure), PARAESTHESIA (prickling/tingling), PRURITUS (rash still evident and sever itching continues on forhead, eyebro and scalp) and EYE PRURITUS (red/itchy eyes). On 09-Mar-2021, HERPES ZOSTER (Shingles) had resolved. At the time of the report, HEADACHE (headache/intense localiged headache), ERYTHEMA (scalp redness/redness), BLOOD PRESSURE INCREASED (elevated blood pressure), RASH (rash breakout on forhead and eyelide (unable to open)), PARAESTHESIA (prickling/tingling), SWELLING OF EYELID (unable to opne eye due to swollan watery eyelid), PRURITUS (rash still evident and sever itching continues on forhead, eyebro and scalp), EYE PRURITUS (red/itchy eyes), VISION BLURRED (vision was densly blurry), PHOTOPHOBIA (light senstivity/tearing frequently) and LACRIMATION INCREASED (light senstivity/tearing frequently) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 12-Feb-2021, Computerised tomogram: negative Negative. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments. No concomitant medications were provided. No treatment details were provided. This case was linked to MOD-2021-032861 (Patient Link). Most recent FOLLOW-UP information incorporated above includes: On 23-Apr-2021: Non-significant; On 29-Jun-2021: Significant follow-up information received.